Novartis returns to Basel after U.S. regulatory meetings

Novartis flew from Morristown Municipal Airport in New Jersey to EuroAirport Basel Mulhouse Freiburg on May 28, 2026, a 7-hour-25-minute transatlantic crossing in its Dassault Falcon 7X HB-JFQ. The overnight flight departed shortly after midnight Eastern time and touched down in Basel at 7:26 a.m. local time.

The same week, per a public FDA calendar, the agency’s Oncologic Drugs Advisory Committee is scheduled to review Novartis’s application for a new radiotherapy treatment target. Morristown’s airport sits seven miles from Novartis’s U.S. headquarters in East Hanover, New Jersey. That proximity makes KMMU the natural launch point for executives shuttling between regulatory meetings in the Washington D.C. area—just a 45-minute flight south by Falcon 7X—and the Basel boardroom.

This particular flight appears to be a return leg after what was likely a series of meetings ahead of that FDA committee date. Novartis’s corporate aviation facility in Basel, with a fleet of three Falcon 7X jets operated through Japat AG, enables that kind of last-minute transatlantic schedule: fly the team to the U.S., hold the meetings, then reposition the aircraft empty or with a reduced load to bring executives back for a Thursday morning in Basel.